Adjuvant Bidirectional Chemotherapy Using an Intraperitoneal Port

Table 2

Four different combined intraperitoneal and intravenous chemotherapy (bidirectional) treatment options.

Disease	Combined intraperitoneal and intravenous chemotherapy treatment option
Peritoneal mesothelioma	Pemetrexed (500 mg/m^2) in 1000 mL 1.5% dextrose peritoneal dialysis solution as a 60-minute rapid infusion through the intraperitoneal port. Cisplatin (75 mg/m^2) in 250 mg of normal saline is given over 120 minutes immediately following the pemetrexed infusion.
Adenocarcinoma	5-fluorouracil (600 mg/m^2) in 1000 mL 1.5% dextrose peritoneal dialysis solution through the intraperitoneal port with the administration as rapid as possible. After the intraperitoneal chemotherapy infusion is complete, oxaliplatin (130 mg/m^2) in 250 mL of dextrose in water is given as a 2-hour intravenous infusion.
Pancreas cancer	Gemcitabine (1000 mg/m^2) in 1000 mL 1.5% dextrose peritoneal dialysis solution through the intraperitoneal port as rapid as possible is given on days 1, 8, and 15 of a 4-week cycle.
Papillary serous and ovarian cancer	Paclitaxel (20 mg/m^2) in 1000 mL 6% Hetastarch through the intraperitoneal port. Intravenous cisplatin (75 mg/m^2) is given after the paclitaxel infusion is complete over 120 minutes.